Transforming growth factor beta isoform (TGF-β (often further specified as TGF-β1, TGF-β2, or TGF-β3))

Transforming growth factor beta isoforms (TGF-β1, TGF-β2, and TGF-β3) are structurally related multifunctional cytokines belonging to the TGF-β superfamily, produced as precursor proteins that form latent complexes requiring activation for function[5][7]. These isoforms regulate a wide array of biological processes, including cell growth, differentiation, apoptosis, immune responses, extracellular matrix deposition, and tissue homeostasis[5][3][7]. The mature TGF-β protein is a homodimer that signals by binding to type II and then type I serine/threonine kinase receptors, resulting in activation of intracellular SMAD transcription factors and modulation of gene expression[5][4][6]. TGF-β signaling is tightly controlled at multiple levels, including ligand activation, receptor engagement, and intracellular signaling events[1][2]. Dysregulation of TGF-β isoforms and their signaling pathways is implicated in numerous diseases, notably cancer (where TGF-β can act as both tumor suppressor and promoter depending on stage and context), fibrotic diseases, immune disorders, and cardiovascular conditions[3][7]. Therapeutic approaches targeting TGF-β isoforms include neutralizing antibodies, ligand traps, and kinase inhibitors; however, systemic blockade presents challenges due to the pleiotropic functions of TGF-β and potential for significant side effects[3].

Other names

TGF-betaTGFβTGFB1TGFB2TGFB3Transforming growth factor betaLatency-associated peptide (LAP, for precursor form)Pro-TGF beta

Ligand sequestration/neutralization (monoclonal antibodies against TGF-β isoforms); Inhibition of TGF-β receptor serine/threonine kinase signaling (small molecule or antibody); Inhibition of downstream SMAD activation; Disruption of latent TGF-β complex activation/release